Objectives: Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented.
Patients And Methods: Twenty-one HIV-infected patients with suppressed HIV replication (<50 copies/mL) for at least 6 months and without previous failure while receiving a protease inhibitor-based regimen started lopinavir/ritonavir monotherapy. Follow-up was performed within the OK pilot clinical trial during the first 2 years and according to routine clinical practice during the 3rd and 4th years.
Results: Fourteen patients (67%) remain on monotherapy and with RNA <50 copies/mL (intention-to-treat analysis, with missing patients scored as failures). Five patients (24%) had virological rebound and all of them were successfully re-suppressed by adding two nucleosides. No major protease inhibitor mutations were found.
Conclusions: Our data support the long-term efficacy and safety of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression, a finding that must be confirmed in larger studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkn103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).
BMC Infect Dis
December 2024
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.
Background: Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral protease, administered to prevent the progression of SARS-CoV-2 infection in patients at high risk for severe COVID-19. We present a real-life case-control study evaluating the efficacy of N/r therapy in SARS-CoV-2 omicron variants positive outpatients in Campania region, Italy, with the aim of assessing the occurrence of three outcomes (hospital admission, admission in ICU and death) in cases and controls.
Methods: We enrolled SARS-CoV-2 positive subjects that came to our attention in Early antiviral treatment ambulatory of Infectious Diseases ward of University Federico II of Naples, Italy from January 1st, 2022, to December 31st, 2022, during the first five days from symptoms occurrence.
Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.
J Infect Dev Ctries
August 2024
Department of Cardiology, Shidong Hospital, Yangpu District, Shidong Hospital affiliated to University of Shanghai for Science and Technology, 999 Shiguang Road, Shanghai 200438, China.
Article Synopsis
- - Paxlovid (nirmatrelvir/ritonavir) is an innovative oral antiviral medication for mild to moderate COVID-19, given over five days; this meta-analysis assessed its effectiveness based on various studies up to March 2023.
- - The findings showed that Paxlovid significantly reduced risks of hospitalization, all-cause mortality, and ICU admissions, as well as shortened hospital stays and viral clearance time compared to control groups.
- - Despite these benefits, no significant differences were observed regarding COVID-19 rebound rates between Paxlovid and control groups, highlighting its overall effectiveness as a treatment option for COVID-19 patients.
The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
Ren Fail
December 2024
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Objectives: Effectiveness of nirmatrelvir/ritonavir (NR) in kidney transplant recipients (KTRs) infected COVID-19 for more than 5 days has not been evaluated.
Methods: In this multicenter retrospective study, 85 KTRs with COVID-19 were enrolled, including 50 moderate, 21 severe, and 14 critical patients.
Results: The median time from onset to starting NR treatment was 14 (IQR, 11-19) days.
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis.
Am J Emerg Med
November 2024
Department of Pharmacology and Toxicology, Pharmacy College, Tikrit University, Tikrit, Iraq.
Article Synopsis
- The COVID-19 pandemic has led to millions of deaths globally and raised questions about effective pharmacological treatments since its onset.
- This paper presents a bibliometric analysis of research on COVID-19 treatments published between 2019 and 2022, focusing on safety and efficacy of various drugs such as Remdesivir and Nirmatrelvir/Ritonavir.
- Although some medications show promise, like Remdesivir in reducing severe outcomes, others like Lopinavir/Ritonavir and Ivermectin yield mixed results, suggesting a need for a combined approach to treatment.
Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19.
Microorganisms
August 2024
Department of Microbiology and Immunology, Seoul National University College of Medicine, 103, Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
The spread of COVID-19 has significantly increased research on antiviral drugs and measures such as case isolation and contact tracing. This study compared the effects of lopinavir/ritonavir and remdesivir on COVID-19 patients with a control group receiving no antiviral drugs. Patients confirmed to have a SARS-CoV-2 infection via real-time RT-PCR were divided into three groups: lopinavir/ritonavir, remdesivir, and control.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!